Establishment of MR-proADM as novel biomarker for individualization of antihypertensive therapy in renal failure patient

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08101
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Oita University
• Principal Investigator: Itoh Hiroki 大分大学, 医学部, 教授 (50420641)
• Co-Investigator(Kenkyū-buntansha): 鈴木 陽介 大分大学, 医学部, 薬剤主任 (10737191)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: MR-proADM / 降圧治療抵抗性

Outline of Final Research Achievements

In this study, we evaluated the efficacy of mid-regional pro-adrenomedullin (MR-proADM) as novel biomarker for individualization of antihypertensive therapy in renal failure patient. Firstly, in kidney transplant recipients, the relationship between resistance to antihypertensive therapy and plasma MR-proADM level was evaluated. Plasma MR-proADM levels before and at 7, 14, 30, 90 and 180 days after kidney transplantation were determined using an enzyme immunoassay. To evaluate resistance to antihypertensive therapy, treatment intensity score of the antihypertensive drugs in each recipient was calculated. A significant negative correlation was observed between treatment intensity score and eGFR at 14 days after kidney transplantation, whereas no significant correlation was observed between treatment intensity score and plasma MR-proADM level. Presently, we are conductiong the prospective cohort study for chronic renal insufficiency patients with resistance to antihypertensive therapy.

Free Research Field

生理活性ペプチド